Controlled-release composition

Claim 2

A controlled-release pharmaceutical dosage component for hard gelatin capsule unit dosage forms comprising a microcapsule prepared by organic phase separation with polyethylene as a phase separation inducing agent consisting of a film of hydrophobic ethylcellulose polymeric material encapsulating a core substantially in the form of an extruded spherule of approximately 420 to 1190 micron diameter and comprising from about 3 to 80 percent by weight of a bronchodilator agent of the β-adrenergic agonist type (in admixture with a pharmaceutically acceptable excipient), at least 10 percent by weight of microcrystalline cellulose and any remainder being conventional pharmaceutical excipients.

Claim 3

A controlled-release pharmaceutical dosage component according to claim 1 wherein the broncholidator agent of the β-adrenergic agonist type is selected from the group consisting of 3,4-dihydroxy-α-[(methylamino)methyl]benzenemethanol, α-[1-(methylamino)ethyl]benzenemethanol, α-(1-aminoethyl)benzenemethanol, α-(1-aminopropyl)-3,4-dihydroxybenzenemethanol, 3,4-dihydroxy-α-[(isopropylamino)methyl]benzenemethanol, 3,5-dihydroxy-α-[(isopropylamino)methyl]benzenemethanol, 3,4-dihydroxy-α-<{[2-(3,4-methylenedioxyphenyl)-1-methylethyl]- amino}methyl>benzenemethanol; α[(tert-butylamino)methyl]-3,4-dihydroxybenzenemethanol, α-[(tert-butylamino)methyl]-3,5-dihydroxybenzenemethanol, 3,4-dihydroxy-α-[1-(isopropylamino)propyl]benzenemethanol, 4-hydroxy-3-(hydroxymethyl)-α-[(tert-butylamino)methyl]benzenemethanol, 4, hydroxy-α-[(isopropylamino)methyl]-3-(methanesulfonamido)benzenemethanol, 3,5-dihydroxy-α-<{[2-(4-hydoxyphenyl)-1-methylethyl]amino}methyl>-benzenemethanol, 3,4-dihydroxy-α-(2-piperidinylmethyl)benzenemethanol, 2-chloro-α-[(isopropylamino)methyl]benzenemethanol, 3-hydroxy-α-[(methylamino)methyl]benzenemethanol, 4-hydroxy-α-[(isopropylamino)methyl]benzenemethanol, 4-(p-chlorophenyl)-4-hydroxy-2-methylpyrrolidine, 8-hydroxy-6-[1-hydroxy-2-(isopropylamino)ethyl]quinoline, α-[(tert-butylamino)methyl]-4-hydroxy-3-(methylsulfonylmethyl)benzenemethanol, a compound having the formula ##STR2## wherein in each of the above formulas: R is hydrogen, alkyl having 1-4 carbon atoms, or cycloalkyl having 3-6 carbon atoms; R' is hydrogen or alkyl having 1-3 carbon atoms; Y is an acyl member which is alkanoyl having 1-22 carbon atoms, alkenoyl having one or two double bonds and having 4-22 carbon atoms, cycloalkyl--C n H 2n --CO-- having a total of 4-10 carbon atoms of which 3-7 are ring carbon atoms in cycloalkyl and wherein n is zero, one or two, 1- or 2-adamantanecarbonyl, phenoxyacetyl, naphthalenecarbonyl, pyridinecarbonyl, or Z--C n H 2n --CO-- wherein n is zero, one or two and Z is phenyl or phenyl substituted by 1-3 members of the group consisting of alkyl having 1-4 carbon atoms, alkoxy having 1-4 carbon atoms, halo, trifluoromethyl, dialkylamino having 2-8 carbon atoms, and alkanoylamino having 1-6 carbon atoms; and Y 1 and Y 2 are the same or different and are hydrogen or one of the acyl members defined by Y; and pharmaceutically-acceptable acid-addition salts thereof.

Claim 4

A controlled-release pharmaceutical dosage component according to claim 2 wherein the bronchodilator agent is a compound having the formula ##STR3## wherein in each of the above formulas: R is hydrogen, alkyl having 1-4 carbon atoms, or cycloalkyl having 3-6 carbon atoms; R' is hydrogen or alkyl having 1-3 carbon atoms; Y is an acyl member which is alkanoyl having 1-22 carbon atoms, alkenoyl having one or two double bonds and having 4-22 carbon atoms, cycloalkyl--C n H 2n --CO-- having a total of 4-10 carbon atoms of which 3-7 are ring carbon atoms in cycloalkyl and wherein n is zero, one or two, 1- or 2-adamantanecarbonyl, phenoxyacetyl, naphthalenecarbonyl, pyridinecarbonyl, or Z--C n H 2n --CO-- wherein n is zero, one or two and Z is phenyl or phenyl substituted by 1-3 members of the group consisting of alkyl having 1-4 carbon atoms, alkoxy having 1-4 carbon atoms, halo, trifluoromethyl, dialkylamino having 2-8 carbon atoms, and alkanoylamino having 1-6 carbon atoms; and Y 1 and Y 2 are the same or different and are hydrogen or one of the acyl members defined by Y; or a pharmaceutically-acceptable acid-addition salt thereof.

Claim 5

A controlled-release pharmaceutical dosage component according to claim 3 wherin the bronchodilator agent is 3,4-bis-(p-toluyloxy)-α-[(tert-butylamino)methyl]benzenemethanol or a pharmaceutically-acceptable acid-addition salt thereof.

Claim 6

A controlled-release pharmaceutical dosage component according to claim 4 wherein the film of hydrophobic polymeric material consists of ethylcellulose.

Claim 7

A controlled-release pharmaceutical dosage component according to claim 5 wherein the film of ethylcellulose constitutes from about 1 to 5 percent by weight of the microcapsule.

Claim 8

A controlled-release pharmaceutical dosage component according to claim 6 wherein the film of ethylcellulose constitutes from about 3 to 4 percent by weight of the microcapsule and the core comprises about 12 percent by weight of 3,4-bis-(p-toluyloxy)-α-[(tert-butylamino)methyl]benzenemethanol or an acid-addition salt thereof, about 19 percent by weight of microcrystalline cellulose, about 50 percent by weight of lactose, about 16 percent by weight of starch and about 3 percent by weight of a starch paste comprising about 15 percent by weight of starch in water.

Claim 9

A pharmaceutical formulation in unit dosage form comprising a controlled-release component according to claim 1.

Claim 10

A pharmaceutical formulation in unit dosage form comprising a controlled-release component according to claim 3.

Claim 11

A pharmaceutical formulation in unit dosage form comprising a controlled-release component according to claim 7.

Claim 12

A pharmaceutical formulation according to claim 10 in the form of a hard gelatin capsule.

Claim 13

A pharmaceutical formulation according to claim 11 wherein the controlled-release component thereof contains a total of about 4 to 16 mg. of 3,4-bis-(p-toluyloxy)-α-[(tert-butylamino)methyl]benzenemethanol or a pharmaceutically-acceptable acid-addition salt thereof.